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Antiretroviral drug therapy and cytotoxic T lymphocytes (CTL) both exert selective pressures on human
immunodeficiency virus type 1, which influence viral evolution. Compared to chronically infected, antiretro-
viral-untreated patients, most chronically infected, treated patients with detectable viremia lack a cellular
immune response against the Gag 77–85(SL9) epitope but show a new immunodominant response against an
epitope in protease PR 76–84. Hence, mutations induced by antiretroviral therapy likely alter the profile of
epitopes presented to T cells and thus the direction of the response. The consequences of dual pressures from
treatment and CTL need to be considered in monitoring of drug therapy.
The course of human immunodeficiency virus type 1
(HIV-1) infection is characterized by the development of an
intricate CD8 cytotoxic T-lymphocyte (CTL) response di-
rected against an evolving viral genome (24). CTL pressure can
lead to early escape from a dominant epitope, as shown in the
simian immunodeficiency virus model, where pressure on Tat
leads to rapid escape and a change in dominance to recogni-
tion of the Gag CM9 epitope (3). A different pattern of chang-
ing epitopic usage over time is illustrated by responses to the
immunodominant HLA-A2-restricted Gag 77–85 (77SLYNTV
ATL85 [SL9]) epitope in p17 Gag. SL9 is recognized by the
majority of chronically infected individuals but not by most
acutely infected individuals (4, 10, 16, 18, 21, 24, 37). This
temporal relationship for CTL recognition of virus proteins/
epitopes is also supported by observations that the HIV-1-Nef
protein is recognized before other proteins (2, 5, 9, 28) and, in
mouse models, by constantly evolving CTL immunodominance
(7, 42–44).
In addition to CTL, therapy with antiretroviral drugs also
exerts significant pressures on the viral genome. This treat-
ment-associated pressure is largely direct and can lead to the
rapid accumulation of drug-resistance associated mutations.
Among treated patients with drug-resistant HIV, the steady-
state viral load is often lower than the pretreated levels. This
partial viral suppression is due in part to residual activity of
antiretroviral drugs and reduced replicative capacity of the
drug-resistant variants (6, 13). We and others, however, have
argued that drug treatment may exert pressure indirectly via
the immune system (1, 12, 23, 36, 38). This interaction can
occur via a number of non-mutually exclusive mechanisms,
including treatment-mediated selection of new mutations that
act as novel epitopes (23, 31–33, 39–41) and/or treatment-
mediated decreases in replicative capacity (“fitness”), which
can lead to a reduction in the ability of HIV-1 to destroy
antigen-specific T cells (6, 11, 13, 20).
Although several studies suggest that treatment can modify
viral evolution via its effect on T-cell immunity, no study has
comprehensively studied the impact of treatment on the hier-
archy of immunodominant responses. To address this issue, we
conducted a detailed study of the interactions between viral
sequence changes and the specificity of the cellular immune
responses. We focused our analysis on well-described HLA-
A2-restricted epitopes, including SL9, and studied HLA-A2-
positive treated and untreated subjects during primary and
chronic HIV-1 infection.
A total of 38 HLA-A2-positive subjects were identified from
the UCSF cohorts of primary infection (OPTIONS) (19, 24)
and from the SCOPE cohort of chronically infected subjects
(14) and were divided into three groups. The three groups
were designated as follows. Group 1 contained subjects with
acute infection and who were antiretroviral untreated (n  8;
median viral load of 4.4 logs, median CD4 cell count of 541
cells/mm3 and median estimated duration of infection 8
weeks), group 2 contained subjects with chronic infection and
who were antiretroviral untreated (n 10; median viral load of
4.4 logs, median CD4 cell count of 322 cells/mm3), and group
3 contained subjects with chronic infection and who were pro-
tease inhibitor treated with detectable viremia (n 20; median
viral load of 3.9 logs and median CD4 cell count of 287 cells/
mm3). The protease inhibitor-treated subjects all had devel-
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oped a number of resistance-associated mutations against both
reverse transcriptase and protease inhibitors (23). Viral se-
quence data were generated using population-based sequenc-
ing from extracted viral RNA in plasma [Dynabeads
Oligo(dT)25; Invitrogen Corporation, Dynal Biotech, Oslo,
Norway] and viral DNA from peripheral blood mononuclear
cells (QIAamp DNA blood kit; QIAGEN, Valencia, CA), as
indicated in Table 1. Sequences obtained from the same indi-
vidual originating from viral DNA and RNA always aligned
together and showed high sequence identity with each other.
When available, sequences obtained from viral RNA in plasma
were used in the sequence analysis. The study was approved by
the UCSF Institutional Review Board, and all subjects pro-
vided written informed consent.
We first analyzed CTL responses targeting SL9 in a group of
20 chronically HIV-1-infected, antiretroviral-treated subjects
with detectable viremia. Surprisingly, we found that these
individuals generally lacked a response against this epitope.
Using the intracellular cytokine flow cytometry (ICS) assay
(23, 24), only 3 of 20 patients had a detectable CTL response
measured by the production of interferon gamma (IFN-)
against the SL9 epitope. Prior studies have repeatedly
shown responses to the SL9 epitope in the majority of
chronically infected, antiretroviral-untreated subjects (4, 18,
21, 22, 37), although these responses were not always im-
munodominant (8).
To evaluate if the lack of T-cell responses to SL9 were
influenced by treatment exposure and sequence changes, we
performed additional studies assessing Gag-, Env-, Nef-, and
Pol-specific responses from 10 antiretroviral-treated and 10
antiretroviral-untreated subjects with chronic infection (Table
1). Using the sequence information obtained by population-
based sequences of the Gag p17, protease, reverse transcrip-
tase (partial), and Nef regions, we manufactured peptides cor-
responding to a panel of 20 epitopes and measured HIV-1-
specific IFN- and tumor necrosis factor alpha (TNF-) CTL
responses using the ICS assay corresponding to autologous and
consensus B sequences (Fig. 1) (24). As has been observed by
others (4, 18, 21, 22, 37), the majority of chronically infected,
TABLE 1. Patient characteristics and treatment history of chronically untreated and treatment-experienced HIV-1-infected subjects
Patient Viral load(copies/ml)
CD4 count
(cells/mm3) Treatment
a
Origin of viral sequences
Gag Pol Nef
Chronically infected, untreated
1028 8,626 411 Last meds in 1992; no PIs RNA/DNA RNA RNA
1029 2,062 373 Never RNA RNA RNA
1030 201,304 258 Never RNA/DNA RNA RNA
1034 34,004 365 Never RNA RNA RNA
1038 27,846 178 Never RNA/DNA RNA RNA
1051 65,276 238 Last meds in 1998; no PIs RNA RNA RNA
1057 8,638 216 last meds in 1999; no PIs RNA RNA RNA
1058 63,932 585 Never RNA/DNA RNA RNA
1074 9,946 688 Never RNA RNA RNA
1079 25,655 438 Never RNA RNA RNA
Chronically infected, treated
(viremic)
3002 6,655 195 16 yr; PIs for 5 yr RNA RNA RNA
3007 8,712 288 14.5 yr; PIs for 5.5 yr RNA/DNA RNA RNA
3011 7,585 125 6.75 yr; PIs for 4 yr RNA/DNA RNA RNA/DNA
3040 21,487 237 10 yr; PIs for 10 yr RNA/DNA RNA DNA
3042 278 160 3.75 yr; PIs for 3 yr RNA/DNA RNA RNA/DNA
3057 20,760 514 10 yr; PIs for 6 yr RNA/DNA RNA RNA/DNA
3109 13,731 296 13 yr; PIs for 6 yr DNA RNA/DNA RNA/DNA
3151 28,610 184 4.5 yr; PIs for 2 yr RNA/DNA RNA/DNA RNA/DNA
3153 5,630 454b 13 yr; PIs for 4 yr RNA/DNA RNA/DNA RNA/DNA
3156 175,000 891 1.5 yr; PIs for 1 yr RNA/DNA RNA/DNA RNA/DNA
a meds, medications; PIs, protease inhibitors.
b Estimated.
FIG. 1. Antiviral treatment alters the distribution of epitope rec-
ognition. Most chronically infected, antiretroviral-treated patients
have gained a response targeting an epitope, which is under strong
protease inhibitor-mediated drug pressure (PR 77–85). In contrast to
the untreated chronically infected subjects, the treated individuals
generally lack responses against the SL9 epitope. A sample was con-
sidered positive when the responses were at least two times the exper-
imental background and above 0.05% IFN-- and TNF--positive
CD8 CD4 CD3 T cells. *, P  0.01 (Fisher’s exact test).
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untreated subjects had measurable CTL responses targeting
the autologous variant of the SL9 epitope (seven of nine sub-
jects tested) (Table 2). This is in contrast to the chronically
infected, treated individuals, of whom only 2 of 6 had a mea-
surable CTL response against the autologous SL9 epitope (P
0.14; Fisher’s exact test for chronically infected, treated versus
untreated) and 2 of 10 had a response against the wild-type
SL9 epitope (P  0.02). Although the treated individuals
lacked strong SL9-specific responses, they exhibited much
stronger responses directed against an epitope in protease
spanning two amino acid positions associated with resistance to
protease inhibitor treatment (PR76-84) (Table 3). Seven out of
nine antiretroviral-treated, chronically infected patients tested
had a response targeting their autologous variant of the
PR76-84 epitope compared to only 1 of 10 chronically infected,
untreated subjects (treated versus untreated, P 0.01; Fisher’s
exact test) (Fig. 1).
As expected, an extensive number of HIV-1 Pol mutations
were present in and around the protease epitope in the chron-
ically infected, treated individuals (all subjects were receiving a
protease inhibitor-based regimen [Table 3]). Most of these
mutations were found in the flanking regions, and six of seven
patients who had developed the resistance-associated mutation
L90M showed reactivity against the PR 76-84 epitope. Since
the L90M mutation was predicted to introduce an additional
protease cleavage site at position L89 in Pol (NetChop 3.0), it
may have influenced processing and presentation of the
epitope.
We next considered what impact this apparent lack of HLA-
A2-restricted Gag-specific (SL9) responses in favor of Pol-
specific (PR 76-84) responses in treated subjects was having on
viral evolution. It should be emphasized that mutations within
the targeted epitope previously have been shown to lead to a
decay of CTL against the wild-type epitope sequence in
chronic infection (22). If, as suggested by our data, protease
inhibitor treatment leads to a shift in immunodominant CTL
responses from established epitopes (e.g., SL9) to new
epitopes (e.g., PR 76-84), then presumably this lack of CTL
response may facilitate reversion of CTL-induced escape mu-
tations associated with a fitness cost (15, 17, 27). This would be
particularly true for SL9 given evidence that mutations in the
Gag region apparently reduce viral fitness (15, 21, 24, 27, 30,
35). In support of this hypothesis, as shown in Table 2, protease
inhibitor-treated patients exhibited less sequence variation
from the consensus in the SL9 epitope, as compared to un-
treated, chronically infected individuals. Also, compared to the
untreated subjects, the treated subjects had a lower prevalence
of the phenylalanine (79F) mutation in position 3 of the SL9
TABLE 2. Treatment alters viral evolution and influence recognition of the SL9 epitopea
Patient no. and sequence type SL9 sequence Frequency (%) Affinity toHLA-A2 (nM)b
CD8 T-cell response
(% IFN-producing cells)
Wild type Variantc
Reference sequence 77SLYNTVATL85
Chronically infected, untreated
1028 --F--I-V- 100 102 d 
1029 --F------ 70 144  0.286
--F--I---e 30 88  0.451
1030 -----I-V- 90 102 0.184 0.074
-------V-e 10 172 0.184 0.104
1034 -----I--- 100 99  
1038 -----I-V- 80 102  NAf
-------V-e 20 172  NA
1051 --F-AI-V- 100 33  0.336
1057 -----I-V- 100 102 0.087 0.078
1058 -I--LI--- 100 151  0.106
1074 --F--I-V- 100 102 0.170 0.265
1079 -----I--- 100 99 0.156 0.123
Chronically infected, treated (viremic)
3002 -------V- 100 172  NA
3007 --------- 100 162 1.560 NVTg
3011 -------V- 100 172  
3040 -----I-V- 100 102  
3042 --------- 100 162 0.356 NVT
3057 -------V- 100 172  
3109 -----L--- 100 140  NA
3151 -------V- 100 172  NA
3153 --------- 100 162  NVT
3156 -----I-V- 100 102  NA
a Positions 77 to 85 in HXB2 protease.
b Affinity to HLA-A2 as predicted by NetMHC 3.0 (http://www.cbs.dtu.dk/services/NetMHC/).
c Autologous viral variant of the SL9 epitope tested.
d , negative.
e Minor variant.
f NA, not analyzed (CTL response against autologous variant epitope not analyzed due to limitation in cell number).
g NVT, no autologous variant to test.
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epitope (P  0.08; Fisher’s exact test) and a lower prevalence
of isoleucine (82I) or leucine (82L) in position 6 (P  0.02;
Fisher’s exact test). This loss of sequence diversity may reflect
fitness-associated reversion back to wild type in the absence of
any residual CTL activity. It is also possible that treatment-
mediated changes in protease may have led to reduced Gag
polypeptide processing (and reduced fitness) and ultimately to
the emergence of compensatory changes in Gag (29, 34).
These results suggest that treatment-induced sequence varia-
tions can alter immunodominance. The cross-sectional nature
of our study, however, prohibits us from excluding the possi-
bility that the lack of SL9-specific responses in our treated
patients may have existed prior to treatment (and indeed may
have reflected a poor immunologic response leading to the
need to start therapy). A longitudinal study in which patients
are studied before treatment and after long-term virologic
failure is needed to more fully address these issues; however,
such a study may not be feasible given that a large number of
treatment-naı¨ve patients would be needed to be studied as they
failed several sequential regimens over a period of several
years.
To further evaluate how the viral sequence may be changing
at different stages of the infection and under the influence of
antiviral therapy, we used viral epidemiology signature pattern
analysis (25) to compare HIV-1 sequences obtained from our
chronically infected subjects with those observed in eight
HLA-A2-positive untreated subjects at primary infection
(OP177, OP428, OP474, OP488, OP506, OP539, OP581, and
OP583, as described in reference 24). Compared to sequences
from untreated individuals with primary infections, the chron-
ically infected, untreated individuals showed differences at four
amino acid positions within Gag (K30R, V82I, T84V, and
E102D). Positions 82 and 84 fall within the SL9 epitope, and
position 102 is flanking a highly immunogenic region. In con-
trast, compared to sequences from primary infection, se-
quences from the chronically infected, treated subjects showed
differences at only two positions (84 and 102). We next used
the Shannon entropy score (26) to quantify variations in the
protein sequence alignments between the different groups.
Once again, the numbers of sites in the sequences showing a
significant difference were greater between the chronically in-
fected, untreated and treated subjects (nine positions) than
between the chronically infected, treated subjects and un-
treated subjects with primary infections (three positions) (data
not shown). Our sequence data therefore indicate that HIV-1
Gag sequences from chronically infected, treated individuals
are more similar to untreated subjects with primary infection
than chronically infected, untreated subjects. Although we
TABLE 3. Antiretroviral treatment alters viral evolution within the HIV-1 protease region that may influence processing and
recognition of the PR 76–84 epitope
Patient no. and sequence type Sequence of PR 76–84a Affinity toHLA-A2 (nM)b
CD8 T-cell responses
(% IFN--producing
cells)
Wild type Variantc
Reference sequence 64IEICGHKAIGTVLVGPTPVNIIGRNLLTQI93
Chronically infected, untreated
1028 ------------------------------ 4,762 d NVTe
1029 Z-------Z--------------------- 4,762  NVT
1030 -------V---------------------L 4,762  NVT
1034 ------------------------------ 4,762  NVT
1038 -----------------------------L 4,762  NVT
1051 ------------------------------ 4,762 0.116 NVT
1057 ------------------------------ 4,762  NVT
1058 --------E----I---------------- 2,101  
1074 --------Q--------------------- 4,762  NVT
1079 ------------------------------ 4,762  NVT
Chronically infected, treated (viremic)
3002 -------I----------N-------M--- 16,091  
3007 --F----VVZ--------S---------K- 12,353  NAf
3011 V------VLS----------------M--- 4,762 0.505 NVT
3040 -------LTS--------A-------M--L 5,931 0.306 0.619
3042 V----Y-------I---------------- 2,101  
3057 -------TZ---------------S-Z--L 4,762 0.055 NVT
3109 -----Z-T--S--I----A-------MZ-L 2,778 0.427 0.467
3151 -------ITZ----------V----VM-K- 2,247 0.247 0.232
3153 ---------T-----Z----V-----M--L 2,247 1.972 0.559
3156 --Z----Z--------------------ZL 4,762 0.308 NVT
a The sequence from positions 64 to 93 in HXB2 protease is shown. Predicted protease cleavage sites are underlined in the reference sequence. The portion of each
sequence corresponding to the PR 76–84 epitope (76LVGPTPVNI84) is shown in boldface. The letter Z represents viral polymorphism at the nucleic acid level giving
rise to two different amino acid variants, including the wild-type variant.
b Affinity to HLA-A2 as predicted by NetMHC 3.0.
c Autologous viral variant of the PR76–84 epitope tested.
d , negative.
e NVT, no autologous variant to test.
f NA, not analyzed.
11546 NOTES J. VIROL.
have not followed the subjects longitudinally, it is possible that
the potential reversions to a more consensus B-like viral se-
quence may be facilitated by the lack of Gag-specific CTL
responses against the wild-type sequence.
In summary, we found an altered distribution of HIV-1
specific CTL epitope recognition in antiretroviral drug-treated
subjects. Compared to chronically infected, untreated patients,
most chronically infected, treated patients had lost a cellular
immune response against the SL9 epitope but gained a new
immunodominant response against an epitope in PR 76-84.
We thus show that mutations induced by antiretroviral therapy
alter the profile of epitopes presented to T cells and thus the
direction of the response. The consequences of dual pressures
from drugs and CTL need to be considered in monitoring of
drug therapy, and as drug therapy becomes more widespread,
transmission of dual drug and immune-shaped virus popula-
tions will become more prevalent.
The results also open the possibility of manipulating drug-
resistant HIV-1 by targeted CTL boosting or using antiretro-
viral drugs to drive CTL escape reversion. Considering the
important role of the cellular immune responses in durably
controlling drug-resistant HIV-1 (14), we suggest that novel
therapeutic approaches, including epitope-specific vaccina-
tions, could be used to either prohibit the development of
specific resistance-associated mutations or mobilize a response
against the mutant virus.
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tained in this study have been submitted to GenBank and were
given accession no. EU011832 to EU011921.
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